Clinical reference Biomarker Directory
Back to directory

KRAS/NRAS

Established

RAS mutation status determines anti-EGFR therapy eligibility in colorectal cancer; KRAS G12C now has its own targeted drug class.

Also known as KRAS NRAS RAS mutation status KRAS G12C
In plain language

KRAS and NRAS are genes that, when mutated, drive many cancers and also block a certain class of colon cancer drugs from working. A specific type of KRAS mutation now has its own targeted pill treatments, approved as recently as 2024 and 2025 — a genuine breakthrough after this gene was considered impossible to target directly for decades.

Biomarker & context

KRAS and NRAS are RAS-family oncogenes central to the MAPK signaling pathway; activating mutations drive uncontrolled proliferation and are among the most common oncogenic drivers across human cancers, with KRAS alone mutated in about 25% of all cancers.

What it indicates

RAS mutation status (KRAS or NRAS) determines eligibility for anti-EGFR antibody therapy (cetuximab, panitumumab) in metastatic colorectal cancer — any RAS mutation predicts lack of benefit and is a requirement to check before prescribing these drugs.

Diagnosis & clinical testing

Detected via PCR-based mutation testing or NGS panel on tumor tissue; testing must cover the full range of clinically relevant RAS mutation sites (not just the single most common one) since any activating mutation in the RAS pathway confers anti-EGFR resistance.

Guiding treatment

A genuinely major, very recent development: the specific KRAS G12C mutation subtype now has its own targeted drugs — sotorasib and adagrasib — with adagrasib gaining FDA approval for colorectal cancer in 2024 (the first KRAS-targeting drug approved for this cancer type) and sotorasib following with a January 2025 approval in combination with panitumumab, both representing a major shift after RAS was considered "undruggable" for decades.

Clinical significance

Sotorasib and adagrasib (2024-2025 approvals) represent a major breakthrough after RAS was long considered an undruggable target.

References
  1. FDA. (2025). FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer.
  2. MSKCC. (2024). FDA Approves First Colorectal Cancer Treatment that Targets G12C KRAS Gene.